Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.75
Peer-review started: January 20, 2023
First decision: April 13, 2023
Revised: May 22, 2023
Accepted: July 11, 2023
Article in press: July 11, 2023
Published online: September 20, 2023
Processing time: 238 Days and 4.2 Hours
Circulating neural cells (CNCs) is an essential strategy which offers the pentagonal application including the Personalized, Prognostics, Predictive, Preventive, predisposing (5xP) panel in the clinical neurology and Neuro-Science. Therefore, it was aimed to explore the developing picture of CNCs’ behavior of the brain cells in the blood stream. CNCs are an available approach for the preventive Medicine and the personalized/target-based therapy.
This strategy includes and offers: (1) Routinizing the CNCs assay through the high and reliable enumeration of the CNCs; (2) providing the required information’s of CNCs to the neurological clinics for the patients affected with neurological disorders including Alzheimer disease (AD); (3) providing adequate Information on the application of CNCs for the protocol to the target clinical centers for either their referral patients affected with, or predisposed to AD as promptly as possible; (4) highlighting the safety, rapidness of the process, non-invasiveness of the CNCs exploration; and an early/preventive strategic detection of the AD in the probands and the relatives through their pedigree; and (5) considering the pedigree-based analysis for tracing of any micro- and macro-environmental predisposing factors, including nutrition and the history of the neurological based diseases including AD.
In the Alzheimer-prone families, the history of any related clinical sign of the neurological symptoms including light and/or progressive through different generations of the referral suspicious case, could be candidate for exploring CNCs. If there is any persuasive micro-and/or macro-environmental risks, the target of the proband’s offspring may be candidate for the CNCs.
The originality of the provided research is based on the Manuel performance and exploration of the single cell based analysis with high enumeration. This strategy is capable to unmask the heterogeneity, diversity and highlights the specific role of the target proteins, and identification of the novel involvement of additional protein through the developmental stages of AD. Furthermore, by respecting the bridging system between Medicine and Science, and according to the primary results of Electroencephalography, as a golden performance, an innovative, complementary and predictive model is provided in this paper. Finally, based on an early detection, and the developmental process through the passed progressive period of AD, the personalized detection, hopefully, leads to the personalized therapy.
The novel results of the provided manuscript are characterized with: Personalized data; Single cell based strategy; and translatable data for the index case and their relatives; an early detection of the protein expression (PE) and brain channels bridging systems, the personalized therapy, could be translated, either for Alzheimer or the related psychological related to the brain disorders. Hypothetic/heterogenic/diverse results highlight evolutionary course within the brain channels.
Unmasking the diverse pattern of PE of the migrated cells from brain to the blood stream, by an adequate enumeration of the CNCs based on the Manuel analytical approach. Unveil the heterogenic pattern of the analyzed target proteins’ expression. Multi-interaction between brain channels, are considered as the personalizd/constructive markers with unlimited cooperation in health and disease.
Unmasking the role of other candidate protein(s). Considering the informative publication(s) as the complementary educational package. Bridging between Science and Medicine by considering the pedigree based translational system for neuro-model, as an early detective platform. Suggesting for stablishing the Neuro-clinic with the aims including ‘Personalized-Predictive/Early detection/Preventive clinic for the families with ‘Alzheimer disease’ and in future with neuro-genetics disorders’.